Scholar Rock said its investigational therapy helped preserve lean mass among patients taking a powerful weight loss drug.

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...

A new study reveals that bariatric surgery results in significantly greater weight loss compared to popular GLP-1 drugs.

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

According to Adam Parker, founder of Trivariate Research, investors aiming for a defensive approach might want to look at ...

INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

Eli Lilly and Company (NYSE:LLY) may be affected by the CVS formulary change considering it could change how its medication, Zepbound, is viewed when compared to Wegovy. That said, despite possible ...

Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease.

Boston-based Verve is a rare example of a gene editing company targeting a disease that affects a large population, offering ...

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...